ALBUQUERQUE, N.M. Enerpulse Inc. announced today that it has completed a merger transaction with L2 Medical Development Co. Enerpulse said it intends to change the name and symbol of L2 Medical Development Co. within the next two weeks. Common stock of the combined companies will continue to be quoted on the OTC Bulletin Board and the OTC Market Group Inc.’s OTCQB.
Enerpulse designs, develops and manufactures ignition products, incorporating its patented Precise Combustion Ignition (PCI) technology to improve combustion efficiency and stability in all spark ignited internal combustion engines (ICE). This includes those fueled by gasoline and/or gas fuels such as natural gas, compressed natural gas, liquefied natural gas and liquid petroleum gas. The company’s targeted markets include commercial stationary engines, commercial vehicles and passenger vehicles in both OEM and service/aftermarket verticals.
Enerpulse CEO Joe Gonnella stated, "We are pleased to be in the public markets and look forward to enhancing the value of our company for all of our stockholders, both old and new. All of us at Enerpulse intend to expand our company’s business in multiple targeted markets. We believe our PCI technology and related products provide a unique value proposition to consumers, commercial operators and OEMs of spark-ignited ICEs. We do this by cost-effectively enabling reduced fuel consumption, lower exhaust emissions and improved combustion stability.”
Gonnella added, "We believe there is strong consumer and regulatory fundamentals that underlie a compelling and sustainable market demand for Enerpulse’s PCI technology."